Dave Rosa
| Dave Rosa | |
 | |
| Born | United States |
|---|---|
| Occupation | Businessman |
| Contact | |
David Rosa is a medical device expert who currently serves as the president, CEO, and board member of NeuroOne Medical Technologies[1]. He has three decades of experience in senior management, consultancy, and sales at several medical and technological organizations[2].
Rosa's company NeuroOne provides minimally invasive and hi-definition solutions for EEG recording, brain stimulation, and ablation solutions for patients experiencing epilepsy, Parkinson's disease, and other related neurological disorders.
Early Life and Education
Born in 1964[3], Rosa acquired a bachelor’s degree in commerce and engineering at Drexel University between 1981 and 1986. At Drexel University, he also served as the president of the Sigma Alpha Epsilon society[4][5].
He later went on to study for an MBA[6][7] in marketing management at Duquesne University from 1986 and 1989. With an educational background in commerce, engineering, and marketing, Rosa subsequently worked in management, sales, and marketing in the medical technology field.
Career
As an experienced marketing manager, Rosa started his management in senior-level positions as the president and CEO of A-Med systems (1999-2005)[8]. He has also served as president and CEO of three different companies, including MilkSmart Inc. (Aug 2008 - Aug 2009), Sunshine Heart Corporation (Sep 2009 - Dec 2015), and NeuroOne Medical Technologies Corporation (current).
He has served as a board member at many other well-known medical companies, including Osprey Medical (Apr 2008 – Nov 2014) and Catchwind Pediatric Innovations (Apr 2016 – Dec 2017)[9]. Rosa is currently a board member of QX Medical, which he joined in 2009; Biotricity[10][11], which he joined in February 2016; and PeriRX LLC, which he joined in June 2016.
Rosa is also currently serving as a venture partner with FundRX,[12] a venture capital and private equity firm. In January 2013, he volunteered as a regular guest lecturer at Carlson Executive Education, University of Minnesota[13], and is a judge for the Minnesota Cup, an organization that provides capital to deserving early stage medical device companies.
Media Coverage
On September 23, 2019, Rosa’s company announced the release of its first NeuroOne sEEG combination depth and ablation electrode[14][15]. Rosa has also been featured previously on Bloomberg’s Taking Stock show, as well as interviews for local Minneapolis TV and radio shows and been featured in numerous newspaper articles.
According to Rosa and his company, the Evo Cortical Electrode is a thin-film electrode technology which records brain activity. It has the potential to act as a reliable solution for the stimulation and ablation of patients who have epilepsy, Parkinson's disease, and back pain. He emphasized that it was the first true thin film kind to receive US FDA 510(K)[16][17] commercial clearance for recording of brain activity and stimulation of brain tissue for up to 30 days.
References
- ^ About NeuroOne
- ^ Business Leaders. MarketScreener.
- ^ David Rosa. Relationship Science.
- ^ David Rosa. Relationship Science.
- ^ David Rosa. Relationship Science.
- ^ Biotricity appoints medical device expert David Rosa to Board of Directors.
- ^ Medical Technologies Corporation Announces First Sale of sEEG Depth Electrode. Yahoo! Finance.
- ^ NeuroOne(TM) Medical Technologies Corporation Announces First Sale of sEEG Depth Electrode. Denver News.
- ^ MarketWatch.
- ^ NeuroOne Medical Technologies Corporation Receives FDA 510(k) Clearance for Evo(TM) Cortical Electrode. Seattle Bulletin.
